Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

World's first device-based treatment for small abdominal aortic aneurysms based on revolutionary new treatment paradigm

Objetivo

The Angiolutions device is a first-of-its-kind device stopping the life-threatening progression of small abdominal aortic aneurysm (AAA) – a pathological dilation of the aorta.
Angiolutions’ award-winning & patent-protected solution leverages a fundamentally new understanding of AAA growth discovered by the founders at Stanford University. They showed that stiffness gradients between the compliant (healthy) aorta and the adjacent stiff (diseased) aneurysm serve as a motor for AAA growth.
Based on this principle & together with key physicians, we developed a minimally-invasive, non-active aortic implant (class III). The nitinol-based device is positioned adjacent to the aneurysm sack via simple, catheter-based implantation. It is specifically designed to focally increase aortic stiffness in the compliant AAA neck region, thereby reducing stiffness gradients towards the stiff AAA sack that drive aneurysm growth.Hereby we achieve a fast, low-risk, size-stabilizing treatment of small AAA.

Ámbito científico (EuroSciVoc)

Palabras clave

Programa(s)

Tema(s)

Régimen de financiación

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) HORIZON-EIC-2023-ACCELERATOR-01

Ver todos los proyectos financiados en el marco de esta convocatoria

Coordinador

ANGIOLUTIONS GMBH
Aportación neta de la UEn
€ 2 499 999,00
Dirección
VAHRENWALDER STR 269A
30179 HANNOVER
Alemania
Pyme
Sí
Región
Niedersachsen Hannover Region Hannover
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Enlaces
Coste total
€ 3 999 673,50